News | October 07, 2014

Occlutech Obtains European CE Approval for its Dedicated Paravalvular Leak Closure Device

Occlutech CE mark Dedicated Paravalvular Leak Closure Device

October 7, 2014 — Occlutech announced that it has obtained a European CE mark approval for its dedicated Paravalvular Leak Closure Device (PLD). The implant is the world´s first, specifically designed device indicated for the minimally invasive closure of leaks occurring around artificial aortic and mitral valves.

Tor Peters, CEO of the Occlutech Group, commented: "We are extremely pleased to provide patients and cardiologists with this innovative product and expect our PLD to save and significantly prolong lives in this growing patient population."

Occlutech's PLD consists of a flexible nitinol wire mesh with "shape-memory" properties. The implant is available in different configurations, multiple sizes and can accommodate a broad range of paravalvular leak anatomies. With an ageing population requiring increasingly more valve replacement surgeries, the frequency of paravalvular leaks is increasing. The Occlutech PLD implant allows atraumatic, minimally invasive closure of paravalvular leaks. PVL closure using implantable devices is in many cases the only alternative available for patients who are too weak to undergo repeat valve replacement or cardiac surgery.

For more information: www.occlutech.com


Related Content

News | Heart Valve Technology

Sept. 1, 2024 — Researchers at UTHealth Houston have identified genetic variants linked to a rare form of bicuspid ...

Home September 04, 2024
Home
News | Heart Valve Technology

June 27, 2024 — The sheer scale of undiagnosed heart valve disease in our aging population has been revealed for the ...

Home June 27, 2024
Home
News | Heart Valve Technology

June 21, 2024 — UC San Francisco interventional cardiologists and interventional echocardiographers recently performed ...

Home June 21, 2024
Home
News | Heart Valve Technology

June 10, 2024 — Atrium Health Sanger Heart & Vascular Institute has successfully completed the first commercial ...

Home June 10, 2024
Home
News | Heart Valve Technology

April 17, 2024 —CPR Therapeutics, Inc. (CPR-T), an early-stage medtech startup funded by the N.I.H and N.S.F to develop ...

Home April 17, 2024
Home
News | Heart Valve Technology

April 1, 2024 — Roughly 25,000 Americans die each year from valvular heart disease, but researchers from Rutgers Health ...

Home April 01, 2024
Home
News | Heart Valve Technology

January 4, 2024 — Findings from a published case series research letter by the Henry Ford Health Structural Heart ...

Home January 04, 2024
Home
News | Heart Valve Technology

December 22, 2023 — TRiCares SAS (“TRiCares”), a privately held pioneer in the field of minimally invasive treatment of ...

Home December 22, 2023
Home
News | Heart Valve Technology

December 18, 2023 — Death rates related to infective endocarditis declined in most adults across the U.S. within the ...

Home December 18, 2023
Home
News | Heart Valve Technology

December 12, 2023 — Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement ...

Home December 12, 2023
Home
Subscribe Now